A child died after receiving an experimental gene editing treatment in China, but the company developing the therapy did not publicly disclose the death until nearly a year later.
Shanghai-based HuidaGene Therapeutics said on Aug. 5 that a participant in its HG302 trial died in August 2025 after receiving a high dose of the treatment for Duchenne muscular dystrophy, a progressive and life-limiting muscle disease.
The company attributed the death to acute respiratory distress syndrome that developed during a severe immune reaction following the treatment.
HuidaGene did not disclose the boy’s age, treatment date, dose, date of death, or clinical course. The trial record shows that the study enrolled four boys between the ages of 4 and 8 at Shanghai Children’s Medical Center….
Another Child Death in China Gene-Editing Trial Disclosed Nearly a Year Later
